Sign in

    Christopher James

    Managing Director and Senior Research Analyst at FBR & Company

    Christopher James is a Managing Director and Senior Research Analyst at FBR & Company, specializing in biotechnology and pharmaceutical equities. He has actively covered leading biotech firms such as Celgene, Gilead Sciences, Incyte, and Amgen, and is recognized for his deep knowledge of clinical trial pipelines and market catalysts, having ranked among top biotechnology analysts by investor platforms for forecast accuracy and insightful research, with a documented success rate exceeding 60% and consistently positive average returns on his stock calls. With over a decade of experience, James began his Wall Street career at Rodman & Renshaw before joining FBR in 2013 and rising to lead the firm’s healthcare research. He holds FINRA Series 7, 63, 86, and 87 licenses, and is distinguished for his rigorous scientific background and client-focused investment perspectives.

    Christopher James's questions to ZFGN leadership

    Christopher James's questions to ZFGN leadership • Q4 2015

    Question

    Christopher James from FBR & Company asked if Zafgen collected data on choking risk in its studies, given beloranib's impact on hyperphagia, and questioned the mechanics of lifting the clinical hold, such as whether it would be a partial or full removal.

    Answer

    Chief Medical Officer Dennis Kim responded that while choking was not a specific endpoint, no such events were captured in the safety data, and it could be a potential post-marketing study. CEO Tom Hughes added that the company will seek a complete lift of the clinical hold, but the final outcome depends on discussions with the FDA.

    Ask Fintool Equity Research AI